161 related articles for article (PubMed ID: 32691153)
1. Stem signatures associated antibodies yield early diagnosis and precise prognosis predication of patients with non-small cell lung cancer.
Chen SS; Li K; Wu J; Peng ZY; Wang ZD; Wang JC; Xu CW; Zhu CL; Li BC; Ren H; Tang SC; Sun X
J Cancer Res Clin Oncol; 2021 Jan; 147(1):223-233. PubMed ID: 32691153
[TBL] [Abstract][Full Text] [Related]
2. The diagnostic efficiency of seven autoantibodies in lung cancer.
Huang H; Luo W; Ni Y; Sun S; Wang C; Zhang L
Eur J Cancer Prev; 2020 Jul; 29(4):315-320. PubMed ID: 31764214
[TBL] [Abstract][Full Text] [Related]
3. Stem signatures associating SOX2 antibody helps to define diagnosis and prognosis prediction with esophageal cancer.
Peng ZY; Wang QS; Li K; Chen SS; Li X; Xiao GD; Tang SC; Ren H; Wang Z; Sun X
Ann Med; 2022 Dec; 54(1):921-932. PubMed ID: 35382656
[TBL] [Abstract][Full Text] [Related]
4. [Clinical value of tumor-associated autoantibodies in diagnosis of early non-small cell lung cancer].
Ren Z; Ding HM; Qian X; Pan SY
Zhonghua Yu Fang Yi Xue Za Zhi; 2021 Dec; 55(12):1426-1434. PubMed ID: 34963239
[No Abstract] [Full Text] [Related]
5. Significance of tumor-associated autoantibodies in the early diagnosis of lung cancer.
Du Q; Yu R; Wang H; Yan D; Yuan Q; Ma Y; Slamon D; Hou D; Wang H; Wang Q
Clin Respir J; 2018 Jun; 12(6):2020-2028. PubMed ID: 29356386
[TBL] [Abstract][Full Text] [Related]
6. Are circulating autoantibodies to ABCC3 transporter a potential biomarker for lung cancer?
Liu L; Liu N; Liu B; Yang Y; Zhang Q; Zhang W; Yu P; Jin Y; Guo J; Guan S; Sun S; Miao L; Wei J
J Cancer Res Clin Oncol; 2012 Oct; 138(10):1737-42. PubMed ID: 22699933
[TBL] [Abstract][Full Text] [Related]
7. Serum anti-p53 autoantibodies in primary resected non-small-cell lung carcinoma.
Iizasa T; Fujisawa T; Saitoh Y; Hiroshima K; Ohwada H
Cancer Immunol Immunother; 1998 Aug; 46(6):345-9. PubMed ID: 9756419
[TBL] [Abstract][Full Text] [Related]
8. Alteration of circulating natural autoantibodies to CD25-derived peptide antigens and FOXP3 in non-small cell lung cancer.
Zhao H; Zhang X; Han Z; Xie W; Yang W; Wei J
Sci Rep; 2018 Jun; 8(1):9847. PubMed ID: 29959381
[TBL] [Abstract][Full Text] [Related]
9. The preoperative platelet distribution width: A predictive factor of the prognosis in patients with non-small cell lung cancer.
Liu C; Zhang H; Qi Q; Zhang B; Yue D; Wang C
Thorac Cancer; 2020 Apr; 11(4):918-927. PubMed ID: 32061027
[TBL] [Abstract][Full Text] [Related]
10. [Evaluation of the application value of seven tumor-associated autoantibodies in non-small cell lung cancer based on machine learning algorithms].
Hao Y; Wu LN; Lyu YT; Liu YZ; Qin XS; Zheng R
Zhonghua Yu Fang Yi Xue Za Zhi; 2023 Nov; 57(11):1827-1838. PubMed ID: 38008573
[No Abstract] [Full Text] [Related]
11. Seven tumor-associated autoantibodies as a serum biomarker for primary screening of early-stage non-small cell lung cancer.
Chen P; Lu W; Chen T
J Clin Lab Anal; 2021 Nov; 35(11):e24020. PubMed ID: 34555232
[TBL] [Abstract][Full Text] [Related]
12. Serum anti-p53 antibodies in patients with lung cancer.
Mack U; Ukena D; Montenarh M; Sybrecht GW
Oncol Rep; 2000; 7(3):669-74. PubMed ID: 10767388
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of tumor-infiltrating lymphocytes for patients with completely resected stage IIIA(N2) non-small cell lung cancer.
Feng W; Li Y; Shen L; Cai XW; Zhu ZF; Chang JH; Xiang JQ; Zhang YW; Chen HQ; Fu XL
Oncotarget; 2016 Feb; 7(6):7227-40. PubMed ID: 26811495
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of tumor-infiltrating lymphocytes using routine H&E slides predicts patient survival in resected non-small cell lung cancer.
Rakaee M; Kilvaer TK; Dalen SM; Richardsen E; Paulsen EE; Hald SM; Al-Saad S; Andersen S; Donnem T; Bremnes RM; Busund LT
Hum Pathol; 2018 Sep; 79():188-198. PubMed ID: 29885403
[TBL] [Abstract][Full Text] [Related]
15. The Role of Serum Tumor Markers in Follow-up After Surgical Treatment of Malignant Lung Tumors.
Vodicka J; Skala M; Sebek J; Treska V; Fichtl J; Prochazkova K; Vankova B; Svaton M; Pecen L; Topolcan O; Bludovska M; Kucera R
Anticancer Res; 2021 Oct; 41(10):5117-5122. PubMed ID: 34593462
[TBL] [Abstract][Full Text] [Related]
16. EarlyCDT-Lung: an immunobiomarker test as an aid to early detection of lung cancer.
Lam S; Boyle P; Healey GF; Maddison P; Peek L; Murray A; Chapman CJ; Allen J; Wood WC; Sewell HF; Robertson JF
Cancer Prev Res (Phila); 2011 Jul; 4(7):1126-34. PubMed ID: 21733826
[TBL] [Abstract][Full Text] [Related]
17. Clinical implications of p53 autoantibodies in the sera of patients with non-small-cell lung cancer.
Mitsudomi T; Suzuki S; Yatabe Y; Nishio M; Kuwabara M; Gotoh K; Hatooka S; Shinoda M; Suyama M; Ogawa M; Takahashi T; Ariyoshi Y; Takahashi T
J Natl Cancer Inst; 1998 Oct; 90(20):1563-8. PubMed ID: 9790550
[TBL] [Abstract][Full Text] [Related]
18. Gene signatures of tumor inflammation and epithelial-to-mesenchymal transition (EMT) predict responses to immune checkpoint blockade in lung cancer with high accuracy.
Thompson JC; Hwang WT; Davis C; Deshpande C; Jeffries S; Rajpurohit Y; Krishna V; Smirnov D; Verona R; Lorenzi MV; Langer CJ; Albelda SM
Lung Cancer; 2020 Jan; 139():1-8. PubMed ID: 31683225
[TBL] [Abstract][Full Text] [Related]
19. Association of preoperative serum CRP with PD-L1 expression in 508 patients with non-small cell lung cancer: A comprehensive analysis of systemic inflammatory markers.
Akamine T; Takada K; Toyokawa G; Kinoshita F; Matsubara T; Kozuma Y; Haratake N; Takamori S; Hirai F; Tagawa T; Okamoto T; Yoneshima Y; Okamoto I; Shimokawa M; Oda Y; Nakanishi Y; Maehara Y
Surg Oncol; 2018 Mar; 27(1):88-94. PubMed ID: 29549910
[TBL] [Abstract][Full Text] [Related]
20. Combined detection of serum autoantibodies as diagnostic biomarkers in esophagogastric junction adenocarcinoma.
Xu YW; Chen H; Guo HP; Yang SH; Luo YH; Liu CT; Huang XY; Tang XM; Hong CQ; Li EM; Xu LY; Peng YH
Gastric Cancer; 2019 May; 22(3):546-557. PubMed ID: 30426295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
